ALPE D’HUZES_A LIFE CHANGING EXPERIENCE

“Giving up is not an option”

On June 02, 2022, Katharina, daughter of our scientific sales representative Monika Kleu participated in the “Alpe d’HuZes” , a unique sporting event, that raises money for cancer research and for improving the quality of life of people suffering from cancer.
“Giving up is not an option” was the motto of this fundraising event and also the motto of Katharinas Bee Team, together with Gerdi Poelstra-Luurs, that turned out to be a real “A-Team” and successfully climbed the 21 turns (15 km) through the Alpes.

CellSystems GmbH, as joint sponsor, was happy to support this engagement, contributing to the decent amount donated.

Congratulation Bee Team

link

CellSystems mentioned in Labourjournal 1-2/2022

CellSystems offers products for enzymatic cell dissociation (Laborjournal 1-2/2022; link).

 

Additional enzymes for cell dissociation:

Collagenases

Papain

Trypsin

Proteinase K

Lysozyme

 

 

Open Position available

Become a part of our team.

 

We are looking for a talented and motivated candidate:

Account Manager Cell Culture (m/w/d)

(link)

TOP SEARCHES in 2021

TOP 5 Searches at our website

 

CellSystems mentioned in BIOspektrum 2021-07: 3D-Zellkultur

CellSystems offers products for 3D cell culture applications (link)

Interim Audit ISO 9001 : 2015

Our annual Quality Management System audit took place at 12.05.2021.

Thank you to all participants for a successful audit.

General Manager: Markus Gemein

New product category available now: COVID-19/SARS-CoV-2

To support our customers, we initiated a new category group for your COVID-19/SARS-CoV-2 research.

 

For details, follow the link

NEW ! Glucose-6-Phosphate Dehydrogenase, High-Activity, Suspension

Now avaiable:

Glucose-6-Phosphate Dehydrogenase, High-Activity, Suspension
Chromatographically purified for higher specific activity. Same as Code: ZF except assayed using NAD. Phosphohexose isomerase, phosphogluconate dehydrogenase, adenylate kinase and creatine phosphokinase contaminant activities 0.02 %, 0.003 %, 0.002 % and 0.002 % respectively. A suspension in 3.7 M ammonium sulfate.

Activity: ≥ 600 NAD units per mg protein

Unit Definition: One Unit reduces one micromole of NAD per minute at 30 °C, pH 7.8, using glucose-6-phosphate as substrate.

LS004002 – 1 KU

LS004004 – 10 Ku

Bulk requests – contact us

NEW TARGATT™ CHO and HEK293 Master Cell Lines available

Applied StemCell’s (ASC) TARGATT™ technology allows site-specific, irreversible gene insertion (up to 20 kb). ASC has taken its proprietary knockin technology and integrated the system into CHO and HEK293 cells. The TARGATT™ CHO and HEK293 Master Cell Lines have displayed high integration efficiencies and medium to high levels of protein expression. These cell lines have the potential to be used for bioproduction, to establish a mammalian cell-based library for antibody screening, and to construct a naïve IgG library system.

Bronchial/Tracheal Epithelial Cells Used in New Airway Model to Evaluate Therapeutics

A Pre-clinical Model to Evaluate Therapeutics for Respiratory Infections

The current COVID-19 pandemic has highlighted the need for a robust pre-clinical model of the respiratory tract that can allow researchers to accurately and efficiently test potential therapeutic agents against emergent infections like SARS-CoV-2. Influenza and coronaviruses like SARS-CoV-2 utilize the lung and airway cells of the respiratory tract as the main entry point into the body. The authors of a recent publication utilized Lifeline’s Human Bronchial/Tracheal Epithelial Cells (HBTECs) to develop a new high throughput in vitro model with better physiological relevance than current systems that could help expedite timelines to test lifesaving therapeutics.

In addition to HBTECs, Lifeline offers a number of other healthy and diseased state lung and airway cells as well as optimized BronchiaLife™ cell culture media. Click on the links below for more information:

  • Small airway cells
  • Diseased small airway epithelial cells – asthma and COPD
  • Bronchial/tracheal epithelial cells
  • Diseased bronchial/tracheal epithelial cells – cystic fibrosis
  • Bronchial/tracheal smooth muscle cells
  • Lobar bronchial epithelial cells
  • Lung fibroblasts
  • Lung smooth muscle cells
  • Laryngeal epithelial cells
  • BronchiaLife Complete Medium Kit

PREDICT96-ALI Model Developed with Lifeline Bronchial/Tracheal Epithelial Cells

Currently, pre-clinical studies used to test therapeutics for respiratory tract infections utilize high-throughput, low-fidelity in vitro screening with human cell lines and/or low-throughput animal models, both of which are often poorly correlated to human clinical responses resulting in a large percentage of drug failures in clinical trials that extend timelines to finding a successful drug candidate. Here, we summarize research by Gard and Colleagues where they successfully developed a high throughput in vitro human primary airway epithelial cell-based model on the PREDICT96-ALI microfluidics platform that is better able to accurately predict clinical responses compared to traditional screening methods.

Lifeline’s primary HBTECs were cultured in our BronchiaLife media and then differentiated using the HBTEC-ALI differentiation media to create a pseudostratified epithelium at an air-liquid interface (ALI) in the PREDICT96-ALI platform. The polarity of the cells at the ALI is a suitable analogue of in vivo respiratory barrier tissues mimicking a range of physiologically relevant responses. The authors used the healthy baseline airway model to test the system’s permissiveness and response to viral infections using three different strains of Influenza A (IAV), the A/WSN/33 strain, and pandemic strains of H1N1 and H3N2. Infection kinetics were determined using immunofluorescence (IF) and qPCR across a range of multiplicities of infection (MOIs) and time points. And, as a proof-of-concept, viral infection kinetics for a single IAV strain in response to pre-treatment of the airway cells with an antiviral (oseltamivir) was investigated to determine if the system could qualify the efficacy of novel therapeutic compounds.

Airway cells in the PREDICT96-ALI model were shown to be permissive to viral infection as determined by IF and qPCR results where a dose-dependent increase of viral protein and RNA, respectively, is observed as MOI increased from 0.1 – 10. To evaluate the efficacy of the model to test therapeutic agents, the airway cells were treated with the antiviral oseltamivir (Tamiflu) for 2 hrs before viral inoculation (A/WSN/33 H1N1 virus) at various MOIs. Oseltamivir treatment in the PREDICT96-ALI airway model significantly reduced influenza replication, maintained barrier integrity, and had viral copy numbers comparable to those observed in a clinical setting with patients.

Taken together, these promising results demonstrate the permissiveness to infection and the potential of the PREDICT96-ALI airway model as a pre-clinical tool to evaluate potential therapies for combating respiratory infections including SARS-CoV-2 in an efficient, robust, and high-throughput manner. Additionally, compatibility with existing pharmaceutical laboratory infrastructure, convenient readouts for quality control and physiological monitoring, makes this platform suitable across many disease areas and application domains over other micro-physiological systems (MPS). The development of more accurate viral testing systems will undoubtedly aide researchers to screen potential drug treatments faster than ever before.

Tune in for the next installation of our blog featuring new research using Lifeline products and industry highlights. If you have used Lifeline products to further your research, we would love to hear from you.